Key facts
- This page summarizes Srdjan R. Stankovic's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Nov 2022, 15:34.
Srdjan R. Stankovic - 19 Nov 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- President
- Issuer ticker
- ACAD
- Reported as of
- 19 Nov 2022
- Net transaction value
- -$27,834
- SEC form
- 4
- Accepted by SEC
- 22 Nov 2022, 15:34:37 UTC
- Prior SEC filing
- 18 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Austin D. Kim, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Srdjan R. Stankovic filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 22 Nov 2022.
Change
- Previous filing in this sequence was filed on 18 Oct 2022.
- Current net transaction value: -$27,834.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,250
- Change %
- +11%
- Price
- Shares after
- 63,081
- Date
- 19 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
ACAD
transaction
Common Stock
Sale
- Transaction value
- $27,834
- Shares
- -1,847
- Change %
- -2.9%
- Price
- $15.07
- Shares after
- 61,234
- Date
- 21 Nov 2022
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -6,250
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,250
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F4
The restricted stock units vest in four equal annual installments beginning November 19, 2019.